Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 332

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Colchicine in Acute Myocardial Infarction

Open access
Jolly, Sanjit S., d’Entremont, Marc-André, Lee, Shun Fu, Mian, Rajibul, Tyrwhitt, Jessica, Kedev, Sasko, Montalescot, Gilles, Cornel, Jan H., Stanković, Goran, Moreno, Raul, Storey, Robert F., Henry, Timothy D., Mehta, Shamir R., Bossard, Matthias, Kala, Petr, Layland, Jamie, Zafirovska, Biljana, Devereaux, P.J., Eikelboom, John, Cairns, John A., Shah, Binita, Sheth, Tej, Sharma, Sanjib K., Tarhuni, Wadea, Conen, David, Tawadros, Sarah, Lavi, Shahar, Yusuf, Salim · 2025 · New England Journal of Medicine

Abstract

BACKGROUND: Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. METHODS: In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either colchicine or placebo and either spironolactone or placebo. The results of the colchicine trial are reported here. The primary efficacy outcome was a composite of death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization, evaluated in a time-to-event analysis. C-reactive protein was measured at 3 months in a subgroup of patients, and safety was also assessed. RESULTS: A total of 7062 patients at 104 centers in 14 countries underwent randomization; at the time of analysis, the vital status was unknown for 45 patients (0.6%), and this information was most likely missing at random. A primary-outcome event occurred in 322 of 3528 patients (9.1%) in the colchicine group and 327 of 3534 patients (9.3%) in the placebo group over a median follow-up period of 3 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.16; P = 0.93). The incidence of individual components of the primary outcome appeared to be similar in the two groups. The least-squares mean difference in C-reactive protein levels between the colchicine group and the placebo group at 3 months, adjusted according to the baseline values, was -1.28 mg per liter (95% CI, -1.81 to -0.75). Diarrhea occurred in a higher percentage of patients with colchicine than with placebo (10.2% vs. 6.6%; P<0.001), but the incidence of serious infections did not differ between groups. CONCLUSIONS: Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2405922

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

  • Roadmap for alleviating the manifestations of ageing in the cardiovascular system

    Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59

    “…in 2024 sparked debate because colchicine treatment did not reduce the incidence of cardiovascular events in patients with myocardial infarction 279 , whereas a meta-analysis of six randomized clinical trials involving nearly 15,000 patients with previous coronary disease showed a consistent…”

Metadata

Authors
Jolly, S. S., d’Entremont, M.-A., Lee, S. F., Mian, R., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stanković, G., Moreno, R., Storey, R. F., Henry, T. D., Mehta, S. R., Bossard, M., Kala, P., Layland, J., Zafirovska, B., Devereaux, P. J., Eikelboom, J., Cairns, J. A., Shah, B., Sheth, T., Sharma, S. K., Tarhuni, W., Conen, D., Tawadros, S., Lavi, S., & Yusuf, S.
Venue
New England Journal of Medicine
Published
2025-02-13
Volume
392
Issue
7
Pages
633-642
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4404448964
Cited by
332
References
13
FWCI
89.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.